ANDON HEALTH(SZ:002432) 36氪·2025-09-02 00:10Core Viewpoint - The article highlights the significant advancements and growth of Konomai (Beijing) Technology Co., Ltd. in the high-end scientific instrument sector, particularly in the field of ultra-high-performance liquid chromatography (UHPLC), emphasizing its role in the domestic market's shift towards self-sufficiency and reduced reliance on imports [2][5]. Group 1: Company Overview - Konomai has completed a multi-million A+ round of financing led by Jiuan Medical, with funds aimed at accelerating commercialization and continuous innovation in independent research and development [2]. - Founded in 2019, Konomai focuses on the independent research and industrialization of UHPLC technology, with its core founding team averaging nearly 20 years of experience in the life science instrument field [2]. - The company has applied for over 30 patents and software copyrights, including 6 invention patents and 14 utility model patents, as of April 2025 [2]. Group 2: Product and Market Position - Konomai has achieved a 95% localization rate for its product components, significantly contributing to the reduction of procurement costs and enhancing analysis efficiency for clients [3]. - The company has launched a full series of UHPLC products, including automated IVD two-dimensional liquid chromatography systems and intelligent chromatography data management systems [2]. - Since initiating its commercialization strategy in 2023, Konomai has experienced a sales growth rate exceeding 50% annually, with international market growth surpassing 80% [3][4]. Group 3: Investment Perspective - Jiuan Medical's chairman, Liu Yi, emphasizes the importance of collaborating with practical enterprises that can address industry pain points and lead industrial upgrades, focusing on self-research and the domestic scientific instrument market [5]. - Konomai's advancements in the UHPLC sector are seen as pivotal in breaking the long-standing reliance on imports in China's high-end market [5].